Conestat alfa
Ruconest (conestat alfa) is a protein pharmaceutical. Conestat alfa was first approved as Ruconest on 2010-10-28. It has been approved in Europe to treat hereditary angioedemas.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ruconest | Biologic Licensing Application | 2022-10-24 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
61 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hereditary angioedemas | D054179 | EFO_0004131 | 2 | 9 | 13 | 1 | 1 | 23 | |
| Hereditary angioedema types i and ii | D056829 | 2 | 2 | 2 | 1 | 1 | 7 | ||
| Covid-19 | D000086382 | U07.1 | — | 1 | — | 1 | — | 2 | |
| Common variable immunodeficiency | D017074 | EFO_0000367 | D83 | — | — | — | 1 | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Angioedema | D000799 | EFO_0005532 | T78.3 | — | 3 | 4 | — | — | 5 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | 3 | 2 | — | — | 4 | |
| Inflammation | D007249 | — | — | 2 | — | 1 | 3 | ||
| Sepsis | D018805 | A41.9 | — | — | 2 | — | — | 2 | |
| Endotoxemia | D019446 | — | — | 1 | — | 1 | 2 | ||
| Multiple organ failure | D009102 | EFO_1001373 | — | — | 1 | — | 1 | 2 | |
| Innate immunity | D007113 | — | — | 1 | — | — | 1 | ||
| Wounds and injuries | D014947 | T14.8 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Reperfusion injury | D015427 | 2 | 2 | — | — | — | 3 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | 2 | 1 | — | — | — | 2 |
| Kidney transplantation | D016030 | 1 | 2 | — | — | — | 2 | ||
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 2 | 2 | — | — | — | 2 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 2 | — | — | — | 2 |
| Graft rejection | D006084 | — | 2 | — | — | — | 2 | ||
| Ischemic stroke | D000083242 | 1 | 1 | — | — | — | 2 | ||
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | — | — | — | 1 |
| Chronic renal insufficiency | D051436 | N18 | 1 | 1 | — | — | — | 1 | |
| Traumatic brain injuries | D000070642 | S06 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuromyelitis optica | D009471 | EFO_0004256 | G36.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CONESTAT ALFA |
| INN | conestat alfa |
| Description | C1-inhibitor (C1-inh, C1 esterase inhibitor) is a protease inhibitor belonging to the serpin superfamily. Its main function is the inhibition of the complement system to prevent spontaneous activation but also as the major regulator of the contact system. C1-inhibitor is an acute-phase protein that circulates in blood at levels of around 0.25 g/L. The levels rise ~2-fold during inflammation. C1-inhibitor irreversibly binds to and inactivates C1r and C1s proteases in the C1 complex of classical pathway of complement. MASP-1 and MASP-2 proteases in MBL complexes of the lectin pathway are also inactivated. This way, C1-inhibitor prevents the proteolytic cleavage of later complement components C4 and C2 by C1 and MBL. Although named after its complement inhibitory activity, C1-inhibitor also inhibits proteases of the fibrinolytic, clotting, and kinin pathways. Note that C1-inhibitor is the most important physiological inhibitor of plasma kallikrein, fXIa, and fXIIa.
|
| Classification | Protein |
| Drug class | enzyme inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108350 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06404 |
| UNII ID | 5QS67N4551 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Ruconest - Pharming
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 289 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,555 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more